Predictive Oncology (POAI) Competitors

Predictive Oncology (NASDAQ:POAI) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment.

Does the MarketBeat Community favor POAI or TELA?

Predictive Oncology received 89 more outperform votes than TELA Bio when rated by MarketBeat users. However, 74.07% of users gave TELA Bio an outperform vote while only 64.22% of users gave Predictive Oncology an outperform vote.

Company	Underperform	Outperform
Predictive Oncology	Outperform Votes 149 64.22%	Underperform Votes 83 35.78%
TELA Bio	Outperform Votes 60 74.07%	Underperform Votes 21 25.93%

Does the media favor POAI or TELA?

In the previous week, TELA Bio had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 3 mentions for TELA Bio and 2 mentions for Predictive Oncology. Predictive Oncology's average media sentiment score of 1.89 beat TELA Bio's score of 0.94 indicating that Predictive Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Predictive Oncology	Very Positive
TELA Bio	Positive

Which has more volatility & risk, POAI or TELA?

Predictive Oncology has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, TELA Bio has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Do insiders and institutionals hold more shares of POAI or TELA?

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 94.3% of TELA Bio shares are held by institutional investors. 3.4% of Predictive Oncology shares are held by insiders. Comparatively, 6.0% of TELA Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Do analysts prefer POAI or TELA?

Predictive Oncology presently has a consensus price target of $3.00, indicating a potential upside of 212.50%. TELA Bio has a consensus price target of $7.25, indicating a potential upside of 617.82%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts plainly believe TELA Bio is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
TELA Bio	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Is POAI or TELA more profitable?

TELA Bio has a net margin of -60.49% compared to Predictive Oncology's net margin of -1,012.32%. Predictive Oncology's return on equity of -286.30% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-1,012.32%	-286.30%	-122.11%
TELA Bio	-60.49%	-556.18%	-63.13%

Which has preferable valuation & earnings, POAI or TELA?

Predictive Oncology has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.62M	5.28	-$13.98M	-$3.05	-0.31
TELA Bio	$69.30M	0.57	-$46.66M	-$1.39	-0.73

Summary

TELA Bio beats Predictive Oncology on 11 of the 18 factors compared between the two stocks.